Acurx Pharmaceuticals Q3 EPS $(0.24) Vs. $(0.32) Last Year
Portfolio Pulse from Benzinga Newsdesk
Acurx Pharmaceuticals (NASDAQ:ACXP) reported a narrower loss of $(0.24) per share in Q3 compared to $(0.32) per share in the same quarter last year, indicating a 25% improvement in its quarterly losses.

November 14, 2023 | 11:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acurx Pharmaceuticals reported a 25% year-over-year improvement in its quarterly losses, which could be seen as a positive sign by investors.
The reduction in losses for Acurx Pharmaceuticals suggests that the company is moving towards improved financial health, which could lead to increased investor confidence and potentially a positive short term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100